Williams AO/AC Signals W34 2026 — 27 Signals Across 9 Sectors

Edition 18 · August 21, 2026

W33 Scorecard

🔴 MODEL OUTPUT — Published candidates from last week. No edits. No omissions.

Performance of all Category A candidates named in W33. Prices measured from the Thursday close of W33 (2026-08-14) to the Thursday close of W34 (2026-08-21). Alpha Vantage weekly bars — last bar of the trading week.

Result key: ✓ escalation · ✗ signal lost · — holding/no position. Entry Reference = Thursday close of W33 (2026-08-14). W34 Close = Thursday 2026-08-21. Source: radar.db weekly_bars.

Scorecard summary: 6 escalated · 8 lost signal · 10 holding · 8 of 24 positive · Avg Δ: -0.6% · SPY: —

Exit Analysis — W33 Signals

🔴 MODEL OUTPUT — Did the 8 names that lost signal exit on real appreciation or noise?

Eight exits this week — none of them driven by genuine upside. The pattern is predominantly technical resets: AC flipped positive while price actually declined or barely moved. NEM and DOW posted minor gains but not with enough conviction to mark as real appreciation. The week reads as a coordinated mechanical reset across multiple sectors, not a broad-based relief rally.

Summary: 0 real appreciation (0%) · 3 range (38%) · 5 without price support or deterioration (63%)

Portfolio Tracker

🟢 LIVE POSITIONS — Actual entries with real or paper capital. Updated every week.

Mode: Paper

The Number of the Week

🔴 MODEL OUTPUT

27 active signals across 387 tickers analyzed — 7.0% of the universe.

Signal count rises from 24 (W33) to 27 — a modest but notable expansion. Six of those 27 are S2D names (degraded), meaning the AC has crossed positive but without full confirmation on the daily oscillators. The market continues to exhibit pockets of depressed structure across health care, biotech, XLRE, and materials. This is not a broad capitulation — it is a slow, grinding compression that has accumulated over multiple weeks. The patient investor setup is building.

Follow-Up — W33 Key Names

🔴 MODEL OUTPUT

W34 Candidates — Category A

🔴 MODEL OUTPUT — Algorithm-generated. Not editorial picks.

The 27 tickers the model flagged as priority for W35 monitoring. Ordered by price percentile (lower = more depressed relative to 52-week range).

Decision week: W35.
Key watch: ISRG (S2D, p20%) and CCI (S1, p0%) — the two most structurally depressed names with confirmed signal momentum.

S2 Signals — Week 34

🔴 MODEL OUTPUT

Pure S2 — Full Confirmation

None this week.

S2 Degraded — 6 Tickers

These patterns triggered S2D this week: AC has crossed positive while AO remains negative, creating the degraded confirmation window. The clock is running — these need price follow-through in W35 or the signal expires.

Pre-Radar — Approaching the Signal

🔴 MODEL OUTPUT

33 tickers at structural lows (≤p15) with no active signal yet. Names to watch heading into W35.

The Universe

387 tickers · 13 sectors
Sectors covered: XLU, XLI, XLP, XLE, XLF, XLV, XLB, XLY, XLK, XLC, XLRE, IBB, XBI
Market reference: SPY

Active signals by type:

• S1 active: 21
• S2 degraded: 6
• S2 pure: 0
• Tickers at structural lows (≤p15): 14

The Ticker of the Week — Deep Dive

🟡 ANALYST COMMENTARY — Editorial interpretation. Not model output.

ISRG · Intuitive Surgical, Inc.

Why ISRG this week: The stock has declined 30% year-to-date and hit a 52-week low in July 2026 — the first time in years this name has appeared genuinely compressed on price rather than simply expensive. This week it escalated from S1 to S2D, meaning the AC crossed positive while AO remains negative: the first oscillator evidence of potential stabilization at current levels. A world-class business at what the model treats as structural lows deserves a hard look.

The Business

Intuitive Surgical is the dominant player in robotic-assisted surgery, with its da Vinci system installed in thousands of hospitals globally. The recurring revenue model — instruments, accessories, and service contracts on top of initial system placements — generates exceptional cash flow durability. This is not a speculative name; it is a compounder that has traded at a structural premium to the market for the better part of two decades.

Why Depressed

Three converging headwinds drove the 2026 selloff: (1) US procedure volume growth decelerated from mid-teens to high-single-digits, disappointing a market that had extrapolated the post-COVID recovery indefinitely; (2) Chinese manufacturers — led by MicroPort and others — have begun taking market share in Asia-Pacific, creating legitimate long-term competitive risk in a region ISRG had treated as a growth runway; (3) a broad rotation out of healthcare innovation names accelerated the multiple compression. By July, over 12 Wall Street firms had cut price targets. The stock sank to a 52-week low on the combined weight of lower growth expectations and genuine competitive anxiety.

The Setup

At p20% of its 52-week range, ISRG is trading in territory it has rarely visited. The AO remains deeply negative (-81.8), but the AC crossed green this week — a classic early S2D pattern that in the model's historical backtest precedes the better entries. This is not a "buy the dip" call on a deteriorating business. The key question is whether the competitive threat is existential or a share-of-market recalibration in a market that continues to grow overall.

The evidence suggests the latter. Da Vinci's installed base advantage — existing hospital relationships, training infrastructure, service contracts — creates switching costs that Chinese competitors have not replicated at scale in developed markets. The US procedure slowdown is real but reads more like normalization than structural impairment. At current prices, analysts project fair value near $490+ (vs. a prior consensus of ~$600).

Risk Factors

• Chinese competition accelerates faster than expected in EMEA and LatAm
• US procedure volume continues decelerating into 2027
• Regulatory friction around next-generation da Vinci systems delays rollout
• Multiple continues to compress if rates remain elevated (ISRG is a long-duration asset)

The Patient Investor Case

Robotic surgery is a secular trend, not a cycle. The addressable market for minimally invasive procedures continues to expand as aging populations globally undergo more complex surgeries. ISRG's moat — training, installed base, proprietary instruments — is real and durable. A 30% decline on a combination of normalized growth and competitive noise (not competitive defeat) is the kind of setup this model was designed to surface. The S2D signal here does not mean "buy now." It means: the oscillators are starting to agree with the price compression story. Watch W35 for AO confirmation.

Manager Note — W34

🟡 ANALYST COMMENTARY — Portfolio manager's macro read. Not model output.

The market this week is not telling a simple story. Signal count rose to 27 — the third consecutive week of expansion — but exit quality deteriorated sharply: zero real appreciation exits out of eight, with most losses attributed to mechanical AC resets rather than genuine price recovery. That divergence matters. When signals pile up but exits fail to confirm on price, the model is identifying compression without resolution.

The Pre-Radar names are the detail I keep coming back to: 33 tickers at structural lows with no active signal yet. XLP alone carries 11 names (PG, K, STZ, GIS, CAG, CPB, TAP, KR, MCD, NKE, LOW among them) — consumer staples broadly sitting at multi-year price lows. That is not a sector-specific problem; it is a macro signal. Margin compression, rate sensitivity, and post-pandemic demand normalization are all writing themselves into the oscillators simultaneously.

My stance remains neutral with a constructive lean on names that have both structural depth (≤p20%) and fundamental quality. ISRG, CCI, and ORCL fit that profile. I am not adding paper positions this week — I want W35 AO confirmation before committing. The setup is building; patience is the edge.

Published: Friday, August 21, 2026